DRUG CANDIDATES

ICA-105665

ICA-105665 is a novel opener of the KCNQ potassium ion channel which has demonstrated a broad spectrum of activity in preclinical models of both epilepsy and pain.  In Phase I safety studies, the compound was shown to be well tolerated in both healthy volunteers and in epilepsy patients.  ICA-105665 was subsequently studied in patients with photosensitive epilepsy, with two of the four patients tested in the 400mg dose cohort showing a positive response.  This study was subsequently extended to doses of 500mg and 600mg, but due to a serious adverse event in the 600mg dose cohort the study was placed on clinical hold.  In an extension to the multiple ascending dose safety study in healthy volunteers, ICA-105665 continued to be well tolerated at doses up to 600mg.  The Company is currently discussing potential next steps with its advisors and with the FDA, with analysis of the complete data set from both studies ongoing.

In addition, we have identified  several lead  compounds that also target  specific potassiumchannels, which are located primarily on the membrane of nerve cells, or  neurons, present in particular regions of the  central and peripheral nervous system. We have retained all worldwide rights to these compounds. 

   Senicapoc

  Senicapoc is a novel small molecule  

  potassium channel inhibitor that targets a

  calcium-activated potassium channel. This

  target is expressed on a  number of cells

  believed to be important in the

  pathogenesis of inflammatory conditions

  including various cells of the immune and

  inflammatory system. Senicapoc is taken

                                                                          orally once-a dosing. Icagen retains all

                                                                          worldwide rights to senicapoc.